ACTIVE

ANEUROTECH

Financial year 2025 · closed on 31/12/2025
Net result
-701,6 k €
-7.1% YoY
Gross margin
-31,1 k €
+5.3% YoY
Equity
610,9 k €
-53.5% YoY

What does ANEUROTECH do?

ANEUROTECH is a Private limited company incorporated in 2022. Its registered office is in Alken.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0785.263.993
Incorporation
14/04/2022
Legal form
Private limited company
Registered office
Alkerstraat 30 A
3570 Alken · FlandreSee on map
Contributed capital
2 085 358,34 €
Latest accounts
31/12/2025
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 4 financial years

2025202420232022
Income statement
Gross margin-31,1 k €-32,8 k €-93,5 k €-1,8 k €
EBITDA-32,2 k €-33,9 k €-94,4 k €-2,2 k €
Operating result-651,2 k €-614,2 k €-399,1 k €-18,1 k €
Net result-701,6 k €-655,3 k €-313,3 k €-21,9 k €
Balance sheet
Equity610,9 k €1,3 M €2 M €75 k €
Total assets2,9 M €3,4 M €4 M €1,9 M €
Cash1,8 k €13,4 k €205,4 k €3,3 k €
Debts2,3 M €2,1 M €2 M €1,9 M €
Estimate

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€
See the valuation
Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 3 ended

Active mandates

RUDI PAUWELS

Director · since 09 novembre 2022

Active
EB Pharma Developments

Director · since 14 avril 2022 · 0780.755.671

Represented by BUNTINX ERIK

Active

Ended mandates

EB Pharma Developments

Director · since 14 avril 2022 · 0780.755.671

Represented by BUNTINX ERIK

Ended
EB Pharma Developments

Director · 0780.755.671

Represented by Erik BUNTINX

Ended
Rudi Pauwels

Director

Ended
Annual accounts

Full financial information

2025202420232022
Type of accountAbridged modelAbridged modelAbridged modelMicro model
Start of the financial year01/01/202501/01/202401/01/202314/04/2022
Closing of the financial year31/12/202531/12/202431/12/202331/12/2022
Length of the financial year12 months12 months12 months9 months
Filing date31/08/202630/08/202530/08/202431/10/2023
General meeting30/06/202630/06/202528/06/202426/10/2023
Currency of the financial yearEUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

4 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202530/06/202631/08/2026DutchPDF
Abridged model31/12/202430/06/202530/08/2025DutchPDF
Abridged model31/12/202328/06/202430/08/2024DutchPDF
Micro model31/12/202226/10/202331/10/2023DutchPDF
Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 3 ended

Active mandates

RUDI PAUWELS

Director · since 09 novembre 2022

Active
EB Pharma Developments

Director · since 14 avril 2022 · 0780.755.671

Represented by BUNTINX ERIK

Active

Ended mandates

EB Pharma Developments

Director · since 14 avril 2022 · 0780.755.671

Represented by BUNTINX ERIK

Ended
EB Pharma Developments

Director · 0780.755.671

Represented by Erik BUNTINX

Ended
Rudi Pauwels

Director

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Restructuring08/03/2024
    KAPITAAL - AANDELEN - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring09/10/2023
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...) - DIVERSEN
    PDF
  • Other07/09/2023
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Other26/07/2023
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Mandates10/02/2023
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates12/12/2022
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates29/09/2022
    ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Mandates29/07/2022
    ONTSLAGEN - BENOEMINGEN
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-701,6 k €
  2. 2024
    Annual accounts 2024-655,3 k €
  3. 2023
    Annual accounts 2023-313,3 k €
  4. 2022
    Annual accounts 2022-21,9 k €
  5. 14/04/2022
    IncorporationPrivate limited company